What this means for cost
If you qualify, $50 a month is far below any cash price we track. If you do not, these are today's self-pay prices for the same drugs from the makers, and the cheapest programs on our board.
- Medicare GLP-1 Bridge copay$50/moif you qualify, through Dec 31, 2027
- Wegovy from Novo, self-pay$199 to $399/moby dose, the maker's published self-pay price; offer terms on the price tracker pageRead 14 Nov 2026.
- Zepbound from Lilly, self-pay$299 to $449/moby dose, the maker's published self-pay price; offer terms on the price tracker pageRead 14 Nov 2026.
- Foundayo from Lilly, self-pay$149 to $299/moby dose, the maker's published self-pay price; offer terms on the price tracker pageRead 14 Nov 2026.
- Cheapest GLP-1 program, any drug$39/moat Wellmedr, sale price, all inWellmedr: plans and pricesRead 22 Nov 2026. Compounded, not FDA-approved.
Manufacturer savings cards exclude Medicare, so on Medicare the routes are the Bridge, your Part D plan's own coverage, or paying cash.
What happens next
- Within 72 hours of a requestPrior authorization decisions, per CMS's pharmacy guidance.
- December 31, 2027The Bridge and its prior authorization approvals end, per CMS.
Sources
- CMS, "Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries" (May 6, 2026), read 20 Nov 2026
- CMS, Medicare GLP-1 Bridge FAQs, read 20 Nov 2026
- CMS, Medicare GLP-1 Bridge: information for pharmacies, read 20 Nov 2026




